AU-Melbourne-SVHM

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Acute myeloid leukaemia2 trials
• Myelodysplastic syndromes2 trials
• Chronic lymphocytic leukaemia1 trial

Phase

• Phase 32 trials
• Phase 1/21 trial

Status

• Active, not recruiting2 trials
• Recruiting1 trial

Lead sponsor

• Stichting Hemato-Oncologie voor Volwassenen Nederland3 trials

Running trials

• Recruiting

  Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

  NCT05791409· Phase 1/2· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

  Contact: Arnon Kater

• Active, not recruiting

  A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

  NCT04027309· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Active, not recruiting

  A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

  NCT03839771· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic lymphocytic leukaemia1 recruiting